The all-new 2016 Chevrolet Malibu offers exceptional style, safety, and efficiency that will be popular with reps and desirable for fleet managers. Read this whitepaper and infographic that demonstrate the features and technologies that make Chevrolet Malibu a great option for pharma fleets.
How can you get your drug to market faster? Join Hewlett Packard Enterprise and Linguamatics as they discuss accelerating your company’s data analytics capabilities. This Executive Summary will provide case studies that illustrate how you can use analytics across the drug development pipeline to support better-informed business decisions and gain competitive advantage.
With the deadline for EFPIA reporting quickly approaching (on or before June 30, 2016) life sciences organizations leaning on best practices and learnings they have gleaned from the Open Payments Program a.k.a. Sunshine Act. As the relationships between industry and healthcare professionals are often in question, financial disclosure programs showcasing ‘transfers of value’ or forms of remuneration to the HCP is growing to further enable trust between patients, physicians and life sciences. This white paper explores the similarities of what data needs to be captured and available for reporting as well as highlights the differences and challenges of implementing a non-mandated program.
Marketing to physicians is evolving at light speed—are you taking advantage of the latest technologies and platforms to target physicians? MDalert.com’s new white paper provides an overview of the dynamic landscape in micro-targeting physicians, as well as evidence that our new mobile-optimized digital platform drives physician engagement in this era of performance-driven healthcare.
This paper examines the changing environment for marketed, or established, products. Authors discuss emerging markets, recent divestment discussions, challenges in the current model -- and a proposed solution for how biopharmaceutical companies can more effectively manage the routine maintenance required to maximize the value of these product portfolios.
How do you really know if your co-pay program is working? Figuring ROI seems straightforward. But Paul LeVine, Vice President of Analytic Services for TrialCard Market Access Solutions thinks the calculus might require a deeper look than is traditionally given as he explained at the 2nd Annual Coupon and Co-Pay Strategy Summit in Philadelphia in February.
Transitioning Hub programs is daunting. But making a major change can be a necessary step to foster a brand’s performance through improved patient support services. At CBI’s 6th Annual Hub and SPP Model Optimization Conference in Philadelphia this February, Scott Dulitz of Trialcard outlines key points of consideration and best practices to fast track the switch to move forward once you’ve come to the conclusion that a change is necessary.
The U.S. has been among the most sought-after pharmaceutical markets in the world for decades. But accessing this enormous market is not easy. Not only must entrants gain marketing approval from the Food and Drug Administration, they must also ensure access to patients by gaining prescriber and payer acceptance. Meeting the combined challenges of marketing approval, payer acceptance, assured reimbursement and access to patients is the result of a studied and deliberate approach to product development and launch. This studied approach is particularly important in rare disease product categories with low numbers of patients, high development costs and managed care plans focused on controlling spend.
Darryl Williams, Head of Global MDM and Platform Solutions, Health Care, for LexisNexis Risk Solutions discussed the impact of Big Data in the Life Sciences with Fierce Markets on December 8, 2015. This white paper is an expansion of the discussion exploring how and why big data will have a big impact on Life Sciences in 2016 and beyond.
Medication adherence is a broadly recognized problem that affects patients worldwide. While the magnitude of nonadherence depends on the drugs and the specific patient population, the World Health Organization reports that 50 percent of patients do not take medications as prescribed on a global basis. A novel framework that distinguishes different phases of nonadherence and promotes specific strategies that are appropriate to each phase promises to improve adherence, improve clinical outcomes and reduce overall healthcare spending.